ATE489633T1 - Verfahren zum frühzeitigen nachweis herzerkrankungen - Google Patents

Verfahren zum frühzeitigen nachweis herzerkrankungen

Info

Publication number
ATE489633T1
ATE489633T1 AT98923666T AT98923666T ATE489633T1 AT E489633 T1 ATE489633 T1 AT E489633T1 AT 98923666 T AT98923666 T AT 98923666T AT 98923666 T AT98923666 T AT 98923666T AT E489633 T1 ATE489633 T1 AT E489633T1
Authority
AT
Austria
Prior art keywords
test sample
early detection
heart diseases
cardiac
hypoxia
Prior art date
Application number
AT98923666T
Other languages
English (en)
Inventor
Roger Sabbadini
Original Assignee
Lpath Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lpath Inc filed Critical Lpath Inc
Application granted granted Critical
Publication of ATE489633T1 publication Critical patent/ATE489633T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/967—Standards, controls, materials, e.g. validation studies, buffer systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808—Automated or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98923666T 1997-06-10 1998-05-22 Verfahren zum frühzeitigen nachweis herzerkrankungen ATE489633T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4927497P 1997-06-10 1997-06-10
PCT/US1998/010486 WO1998057179A1 (en) 1997-06-10 1998-05-22 Methods for early detection of heart disease

Publications (1)

Publication Number Publication Date
ATE489633T1 true ATE489633T1 (de) 2010-12-15

Family

ID=21958982

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98923666T ATE489633T1 (de) 1997-06-10 1998-05-22 Verfahren zum frühzeitigen nachweis herzerkrankungen

Country Status (8)

Country Link
US (3) US6210976B1 (de)
EP (1) EP0988552B1 (de)
JP (1) JP5264026B2 (de)
AT (1) ATE489633T1 (de)
AU (1) AU7590198A (de)
CA (1) CA2293718A1 (de)
DE (1) DE69842017D1 (de)
WO (1) WO1998057179A1 (de)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6495538B2 (en) * 1999-06-23 2002-12-17 Zinc Therapeutics, Canada Inc. Zinc ionophores as therapeutic agents
WO2001003739A1 (fr) * 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US20100121360A9 (en) * 2000-12-20 2010-05-13 Fox Hollow Technologies, Inc Testing a patient population having a cardiovascular condition for drug efficacy
US7699790B2 (en) * 2000-12-20 2010-04-20 Ev3, Inc. Debulking catheters and methods
US20050154407A1 (en) * 2000-12-20 2005-07-14 Fox Hollow Technologies, Inc. Method of evaluating drug efficacy for treating atherosclerosis
US20030096022A1 (en) * 2000-12-22 2003-05-22 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
JP2002243737A (ja) * 2001-02-09 2002-08-28 Azwell Inc 抗スフィンゴ脂質モノクローナル抗体
US7041468B2 (en) 2001-04-02 2006-05-09 Therasense, Inc. Blood glucose tracking apparatus and methods
US7901873B2 (en) * 2001-04-23 2011-03-08 Tcp Innovations Limited Methods for the diagnosis and treatment of bone disorders
US7202089B2 (en) * 2001-09-14 2007-04-10 Alan Kleinfeld Early diagnosis of stroke
US7262017B2 (en) * 2001-09-14 2007-08-28 Torrey Pines Institute For Molecular Studies Diagnostic markers for ischemia
US7608258B2 (en) * 2002-04-13 2009-10-27 Allan Mishra Method for treatment of tendinosis using platelet rich plasma
US6811777B2 (en) * 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
US7670769B2 (en) 2002-05-09 2010-03-02 The Brigham And Women's Hospital, Inc. IL1RL-1 as a cardiovascular disease marker and therapeutic target
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
US20050014198A1 (en) * 2002-07-11 2005-01-20 Leong Ng Assays and kits for detecting and monitoring heart disease
GB0216191D0 (en) * 2002-07-11 2002-08-21 Univ Leicester Plasma urotensin in human heart failure
CA2500739A1 (en) * 2002-10-09 2004-04-22 Dmi Biosciences, Inc. Diagnosis and monitoring of inflammation, ischemia and appendicitis
GB0224425D0 (en) * 2002-10-21 2002-11-27 Univ Leicester Method for prediction of cardiac disease
WO2004046729A2 (en) * 2002-11-21 2004-06-03 The University Of Leicester Bodily fluid markers of tissue hypoxia
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
AU2003303597A1 (en) 2002-12-31 2004-07-29 Therasense, Inc. Continuous glucose monitoring system and methods of use
WO2004063084A2 (en) * 2003-01-06 2004-07-29 Nutri-Check Technologies, Llc Individual need-based system for providing supplements
US7074194B2 (en) * 2003-05-19 2006-07-11 Ischemia Technologies, Inc. Apparatus and method for risk stratification of patients with chest pain of suspected cardiac origin
US20040244062A1 (en) * 2003-06-02 2004-12-02 Crittenden Jill R. Use of protein inhibitors as antithrombotic agents
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
EP1522857A1 (de) * 2003-10-09 2005-04-13 Universiteit Maastricht Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2
DE10351238A1 (de) * 2003-11-03 2005-06-02 Roche Diagnostics Gmbh Diagnosestellung von akuten myokardialen, ischämischen Erkrankungen durch Kombination von Markern
US20050100964A1 (en) * 2003-11-11 2005-05-12 George Jackowski Diagnostic methods for congestive heart failure
EP1723432A1 (de) * 2004-02-05 2006-11-22 Medtronic, Inc. Verfahren und vorrichtung zur identifizierung von patienten in gefahr durch lebensbedrohliche arrhythmien
US7608458B2 (en) * 2004-02-05 2009-10-27 Medtronic, Inc. Identifying patients at risk for life threatening arrhythmias
EP1718198A4 (de) 2004-02-17 2008-06-04 Therasense Inc Verfahren und system zur bereitstellung einer datenkommunikation in einem kontinuierlichen blutzuckerüberwachungs- und managementsystem
US7601510B2 (en) * 2004-03-22 2009-10-13 Ffa Sciences Llc Development and use of fluorescent probes of unbound analytes
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US8335652B2 (en) * 2004-06-23 2012-12-18 Yougene Corp. Self-improving identification method
US20050287574A1 (en) * 2004-06-23 2005-12-29 Medtronic, Inc. Genetic diagnostic method for SCD risk stratification
US8027791B2 (en) * 2004-06-23 2011-09-27 Medtronic, Inc. Self-improving classification system
US7462268B2 (en) * 2004-08-20 2008-12-09 Allan Mishra Particle/cell separation device and compositions
EP1789806A2 (de) * 2004-09-13 2007-05-30 Lipomics Technologies, Inc. Metabolitmarkierer zur gewichtsverwaltung
US20060199280A1 (en) * 2005-03-03 2006-09-07 David Bar-Or Quantification of proteins
US7794413B2 (en) * 2005-04-19 2010-09-14 Ev3, Inc. Libraries and data structures of materials removed by debulking catheters
US20060246574A1 (en) * 2005-04-29 2006-11-02 Sarah Rosenstein Dispenser for making a lateral flow device
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
US20080254661A1 (en) * 2005-04-29 2008-10-16 Byrne Norman R Center Connect Single-Sided Junction Block
US20060246599A1 (en) * 2005-04-29 2006-11-02 Sarah Rosenstein Lateral flow device
US20060257938A1 (en) * 2005-05-10 2006-11-16 Kleinfeld Alan M Method of screening for drugs that block ligand binding to a lipid binding protein
JP4850001B2 (ja) * 2005-09-05 2012-01-11 プリマハム株式会社 新規ストレスバイオマーカー及びその用途
US20070065954A1 (en) * 2005-09-15 2007-03-22 Minoru Taya Surface plasmon resonance biosensor system for detection of antigens and method for determining the presence of antigens
US20070077200A1 (en) * 2005-09-30 2007-04-05 Baker Clark R Method and system for controlled maintenance of hypoxia for therapeutic or diagnostic purposes
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US7878644B2 (en) 2005-11-16 2011-02-01 Gerber Scientific International, Inc. Light cure of cationic ink on acidic substrates
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
PL2386860T4 (pl) 2006-04-24 2015-09-30 Critical Care Diagnostics Inc Przewidywanie śmiertelności i wykrywanie poważnej choroby
ATE517341T1 (de) * 2006-04-27 2011-08-15 Critical Care Diagnostics Inc Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen
PT2021796E (pt) * 2006-05-01 2012-04-19 Critical Care Diagnostics Inc Diagnóstico de doença cardiovascular
DK2019965T3 (en) * 2006-05-02 2015-07-20 Critical Care Diagnostics Inc DIFFERENTIAL BETWEEN LUNG AND Cardiovascular Disease
US8796429B2 (en) 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US7862812B2 (en) * 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
US9274129B2 (en) * 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US9217749B2 (en) * 2006-05-31 2015-12-22 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
WO2007143225A2 (en) 2006-06-07 2007-12-13 Abbott Diabetes Care, Inc. Analyte monitoring system and method
WO2008060841A2 (en) 2006-10-27 2008-05-22 Ffa Sciences, Llc Use of probes for unbound metabolites
KR101581279B1 (ko) * 2006-10-27 2015-12-31 엘파스, 인크. 스핑고신-1-포스페이트 결합을 위한 조성물 및 방법
CN101687031B (zh) * 2006-10-27 2014-05-14 勒帕斯公司 用于治疗眼疾和眼病的组合物及方法
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
JP5105583B2 (ja) * 2007-03-14 2012-12-26 国立大学法人信州大学 心血管系疾患既往区別方法
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US20100179066A1 (en) * 2007-06-07 2010-07-15 Inserm (Institut National De La Santé Et De La Rec Method for Assessing the Risk of a Cardiovascular Disease and for Diagnosing Dyslipidemia
US20100285446A1 (en) * 2007-07-20 2010-11-11 Akos Vertes Methods for Detecting Metabolic States by Laser Ablation Electrospray Ionization Mass Spectrometry
US8067730B2 (en) 2007-07-20 2011-11-29 The George Washington University Laser ablation electrospray ionization (LAESI) for atmospheric pressure, In vivo, and imaging mass spectrometry
DE102007042986A1 (de) * 2007-09-10 2009-04-23 Siemens Ag Medizinisches Gerät und Verfahren zum Betreiben eines medizinischen Geräts
ES2378010T3 (es) * 2007-09-17 2012-04-04 Bg Medicine, Inc. Valoración de riesgo cardíaco congestivo en pacientes tratados o que potencialmente van a ser tratados con un agonista del receptor gamma activador de proliferador de peroxisoma o una tiazolidinodiona
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
EP2222877A4 (de) * 2007-11-14 2011-10-12 Medtronic Inc Genetische marker für die scd- oder sca-therapieauswahl
US20110143956A1 (en) * 2007-11-14 2011-06-16 Medtronic, Inc. Diagnostic Kits and Methods for SCD or SCA Therapy Selection
WO2009070457A1 (en) * 2007-11-30 2009-06-04 Waters Technologies Corporation Determining the presence or absence of mineralocorticoids in samples
SI2269063T1 (sl) 2008-04-18 2014-01-31 Critical Care Diagnostics, Inc. Napoved tveganja večjih neugodnih pojavov na srcu
US7811749B2 (en) * 2008-04-21 2010-10-12 Abbott Laboratories Measuring free choline to determine suitability of erythrocytes for transfusion
US20100112081A1 (en) 2008-10-07 2010-05-06 Bioparadox, Llc Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities
US8440459B2 (en) * 2008-10-09 2013-05-14 Allan Kumar Mishra Platelet rich plasma formulations for cardiac treatments
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
BRPI0919975A2 (pt) * 2008-10-29 2015-12-15 Bg Medicine Inc imunoensaio para galectina-3
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US20110076697A1 (en) * 2009-04-28 2011-03-31 Innovative Laboratory Technologies, Inc. Lateral-flow immuno-chromatographic assay devices
US9226701B2 (en) 2009-04-28 2016-01-05 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
EP2430184A2 (de) * 2009-05-12 2012-03-21 Medtronic, Inc. Sca-risikostratifizierung durch vorhersage des ansprechens von patienten auf antiarrhythmika
US9184490B2 (en) 2009-05-29 2015-11-10 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
JP5702386B2 (ja) * 2009-08-25 2015-04-15 ビージー メディシン， インコーポレイテッド ガレクチン−３および心臓再同期療法
EP2473098A4 (de) 2009-08-31 2014-04-09 Abbott Diabetes Care Inc Analytsignalverarbeitungsvorrichtung und -verfahren
WO2011026148A1 (en) 2009-08-31 2011-03-03 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
WO2011041469A1 (en) 2009-09-29 2011-04-07 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
WO2011089146A1 (en) 2010-01-20 2011-07-28 Universität Zürich Method for assaying diseases characterised by dyslipidemia
EP3502707A1 (de) * 2010-01-29 2019-06-26 metanomics GmbH Mittel und verfahren zur diagnostizierung von herzinsuffizienz bei einer person
EP2385374B2 (de) 2010-05-05 2018-02-28 Zora Biosciences OY Lipidomik-Biomarker für Atherosklerose und kardiovaskuläre Erkrankung
US9201080B2 (en) 2010-06-20 2015-12-01 Zora Biosciences Oy Lipidomic biomarkers for identification of high-risk coronary artery disease patients
WO2012003475A1 (en) 2010-07-02 2012-01-05 Bg Medicine, Inc. Statin therapy monitored by galectin- 3 measurement
EP2671080A1 (de) 2011-01-31 2013-12-11 BG Medicine, Inc. Verwendung von galectin-3 zur erkennung und prognose von herzinsuffizienz nach akutem koronarsyndrom
CN106940375B (zh) 2011-03-17 2019-03-08 重症监护诊断股份有限公司 预测不良临床结果的风险的方法
WO2013085572A2 (en) 2011-07-14 2013-06-13 The George Washington University Plume collimation for laser ablation electrospray ionization mass spectrometry
WO2013014286A2 (en) * 2011-07-28 2013-01-31 Metanomics Gmbh Means and methods for diagnosing and monitoring heart failure in a subject
US9980669B2 (en) 2011-11-07 2018-05-29 Abbott Diabetes Care Inc. Analyte monitoring device and methods
EP2592423A1 (de) * 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomik-Biomarker zur Prognose von kardiosvaskulären Ergebnissen bei Patienten mit Erkrankung der Herzkranzgefäße ohne Statinbehandlung
EP2592422A1 (de) * 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomik-Biomarker zur Prognose von kardiosvaskulären Ergebnissen bei Patienten mit Erkrankung der Herzkranzgefäße unter Statinbehandlung
CA2862830A1 (en) 2012-01-06 2013-07-11 Bg Medicine, Inc. Use of galectin-3 for risk assessment and detection of preeclampsia and related conditions
HK1212057A1 (en) 2012-08-21 2016-06-03 重症监护诊断股份有限公司 Multimarker risk stratification
US9968306B2 (en) 2012-09-17 2018-05-15 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
US20140356893A1 (en) 2013-06-04 2014-12-04 Allan Mishra Compositions and methods for using platelet-rich plasma for drug discovery, cell nuclear reprogramming, proliferation or differentiation
US10590459B2 (en) 2013-12-20 2020-03-17 The Regents Of The University Of California Biomimetic virus-based colorimetric sensors
KR101799985B1 (ko) 2016-09-02 2017-11-21 아주대학교산학협력단 S1p 및 스핑고신을 이용한 중증천식의 진단방법
JP6883851B2 (ja) * 2017-06-16 2021-06-09 国立大学法人 東京大学 炎症性疾患の診断方法およびそのためのキット、ならびに炎症疾患の治療のための薬物のスクリーニング方法
CN118922721A (zh) * 2022-03-18 2024-11-08 豪夫迈·罗氏有限公司 用于2型与1型急性心肌梗死的早期辨别的cMyBPC标志物组合

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5510590A (en) * 1978-05-04 1980-01-25 Wellcome Found Enzyme immunity quantity analysis
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
JPS6035263A (ja) * 1983-08-05 1985-02-23 Wako Pure Chem Ind Ltd 不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JPH02128697A (ja) * 1988-11-09 1990-05-17 Hoechst Japan Ltd 抗フコシルセラミドモノクローナル抗体
CA2027434C (en) 1990-10-12 1999-01-05 George Jackowski Diagnostic kit for diagnosing and distinguishing chest pain in early onset thereof
US5710008B1 (en) 1990-10-12 1999-09-07 Spectral Diagnostics Inc Method and device for diagnosing and distinguishing chest pain in early onset thereof
US5604105B1 (en) 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
RU2003979C1 (ru) * 1991-06-28 1993-11-30 Московский областной научно-исследовательский клинический институт им.М.Ф.Владимирского Способ прогнозировани течени послеоперационного периода у больных врожденными пороками сердца

Also Published As

Publication number Publication date
CA2293718A1 (en) 1998-12-17
WO1998057179A1 (en) 1998-12-17
JP2002504999A (ja) 2002-02-12
US6534322B1 (en) 2003-03-18
DE69842017D1 (de) 2011-01-05
JP5264026B2 (ja) 2013-08-14
US6210976B1 (en) 2001-04-03
EP0988552B1 (de) 2010-11-24
EP0988552A1 (de) 2000-03-29
AU7590198A (en) 1998-12-30
US6534323B1 (en) 2003-03-18

Similar Documents

Publication Publication Date Title
ATE489633T1 (de) Verfahren zum frühzeitigen nachweis herzerkrankungen
ATE256869T1 (de) Probendetektion zum initiieren der zeitmessung eines elektrochemischen tests
ATE278803T1 (de) Verfahren zur überwachung der proteasomeinhibitorarzneimitteleffekte
ATE408829T1 (de) Verfahren und assaykits zum nachweis mononuklearer zellphänotypen
DE59911618D1 (de) Verfahren zum verbessern der messwerte eines inertialen messsystems
ATE408709T1 (de) Homogenes verfahren zum testen von duplex- oder triplex-hybridisierungen mittels durchführung von mehreren messungen unter verschiedenen bedingungen
ATE509275T1 (de) Schnelltest für glykiertes albumin
ATE279531T1 (de) Test zum nachweis der aktivität von phospho-n- acetylmuramyl-pentapeptid-translokase
DE60116889D1 (de) Test zum direkten nachweis eines inflammatorischen anzeiger in einer körperflüssigkeitsprobe
DE60015726D1 (de) Verfahren und vorrichtung zum vorhersagen von haemostatischer funktionsstörung in patientenproben
EP1221620A3 (de) Verfahren zum Ausführen einer Bestimmung der "activated clotting time" mit geringer Empfindlichkeit gegenüber die Anwesenheit des Aprotinins sowie zur Ermittlung der Aprotinin-Empfindlichkeit
DE60025347D1 (de) Methoden zur vohersage eines schwangerschaftsergebnisses bei einer testperson mit hilfe eines hcg-tests
BR0107984A (pt) Método e dispositivo para efetuar medição de tira de teste
ATE486137T1 (de) Verbessertes einfangen und detektion von zielnukleinsäuren in verfahren mit teststreifen
DE59914830D1 (de) Verfahren und testbesteck zur beurteilung der oxid messung ihrer antiradikalen aktivität
ATE370414T1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
DE60137512D1 (de) Zusammensetzungen und verfahren zum nachweis und zur quantifizierung von cox-2-aktivität und 2-arachidonylglycerin-metaboliten
DE69835301D1 (de) Verfahren zur identifizierug oder testung von agonisten für bzw. antagonisten gegen ppar
DE60118797D1 (de) Verfahren zur detektion und messung der biomasse
DE59905904D1 (de) Vorrichtung zum Messen von Eigenschaften eines längsbewegten Prüfguts
PT1003458E (pt) Teste de funcao hepatica
WO2020102808A3 (en) Oral wash for oral fluid collection and analysis and methods of use thereof
ATE302947T1 (de) Verfahren zum nachweis eines lipoprotein- akutphaseprotein-komplexes
WO2003076896A3 (en) Use of biomarkers to detect breast cancer
ATE103990T1 (de) Verfahren zur diagnose der periodontalen krankheit mittels nachweis von alaninaminotransferase.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties